

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

5

af

7

<i>Complete if Known</i>	
<i>Application Number</i>	10/621,684
<i>Filing Date</i>	July 17, 2003
<i>First Named Inventor</i>	Scott A. Waldman
<i>Art Unit</i>	1639
<i>Examiner Name</i>	Sue Xu Liu
<i>Attorney Docket Number</i>	TJU0001-107 (WAL SCO.001)

## U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No.	Document Number	Publication/Issue Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code* (if known)	MM-DD-YYYY		
	1	US-4,341,763	07-27-1982	Zygraich	
	2	US-5,731,159	03-24-1998	Waldman	
	3	US-4,601,896	07-22-1986	Nugent	
	4	US-4,729,893	03-08-1988	Letcher et al.	
	5	US-4,849,227	07-18-1989	Cho	
	6	US-5,271,961	12-21-1993	Mathiowitz et al.	
	7	US-5,330,892	07-19-1994	Vogelstein et al.	
	8	US-5,350,741	09-27-1994	Takada	
	9	US-5,352,275	10-04-1994	Albertsen et al.	
	10	US-5,399,347	03-21-1995	Trentham et al.	
	11	US-4,845,200	07-04-1989	Cullinan et al.	
	12	US-5,057,313	10-15-1991	Shih et al.	
	13	US-5,166,320	11-24-1992	Wu et al.	
	14	US-5,585,479	12-17-1996	Hoke et al.	
	15	US-5,731,159	03-24-1998	Waldman	
	16	US-5,928,873	07-27-1999	Waldman	
	17	US-6,087,109	07-11-2000	Waldman	
	18	US-7,097,839	08-29-2006	Waldman	
	19	US-5,879,656	03-09-1999	Waldman	
	82	US-6,767,704	07-27-2004	Waldman	

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional).<sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if applicable.<sup>6</sup> Applicant is to place a check mark here if English language transcription is attached.".

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissions for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO				<b>Complete If Known</b>	
				Application Number	10/621,684
				Filing Date	July 17, 2003
				First Named Inventor	Scott A. Waldman
				Art Unit	1639
				Examiner Name	Sue Xu Liu
(Use as many sheets as necessary)				Attorney Docket Number	TJU0001-107 (WAL_SCO.001)
Sheet	2	of	7		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	20	Alexander et al., "Oncogene Alterations in Rat Colon tumors Induced by -methyl-N-nitrosourea," Am. J. Med. Sci. (1992) 303(1):16-24.		T 2
	21	Beck-Sickinger et al., "Neuropeptide Y: Identification of the Binding Site," Int. J. Peptide Protein Res. (1990) 36:522-530.		
	22	Bold et al., "Experimental Gene Therapy of Human Colon Cancer," Surgery (1994) 116(2):189-196.		
	23	Blond-Elguindi et al., "Affinity Panning of a Library of Peptides Displayed on Bacteriophages Reveals the Binding Specificity of BIP," Cell (1993) 75:717-728.		
	24	Bremer and Schwarz, "Safety and Efficacy of Radiopharmaceuticals," Kristensen and Norbygaard, Eds., Martinus Nijhoff, Dordrecht, the Netherlands, pp. 43-50 (1987).		
	25	Ceriani et al., "Variability in surface antigen expression of human breast epithelial cells cultured from normal breast, normal tissue peripheral to breast carcinomas, and breast carcinomas," Cancer Research (1984) 44(7):3033-3039.		
	26	Ceriani et al., "Circulating human mammary epithelial antigens in breast cancer," PNAS (1982) 79(17):5420-5424.		
	27	Ciardiello et al., "Inhibition of CRIPTO Expression and Tumorigenicity in Human Colon Cancer Cells by Antisense RNA and Oligodeoxynucleotides," Oncogene (1994) 9(1):291-298.		
	28	Collins et al., "C-myc Antisense Oligonucleotides Inhibit the Colony-forming Capacity of Colo 320 Colonic Carcinoma Cells," J. Clin. Investigation (1992) 89(5):1523-1527.		
	29	Cooney et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene In Vitro," Science (1988) 241:456-459.		
	30	Cull et al., "Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor," PNAS USA (1992) 89(5):1865-1869.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
(Use as many sheets as necessary)			
Sheet	3	of	7
Attorney Docket Number			
TJU0001-107 (WAL_SCO.001)			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	31	Dayhoff "Atlas of Protein Sequence and Structure", Nat. Biomed. Res. Found., 1978, vol. 5, Supp. 3, Washington, D.C.	
	32	DeVita "Principles of Cancer Therapy" in Harrison's Principles of Internal Medicine, McGraw-Hill, New York, 1983, pp. 765-787.	
	33	Dillman "Monoclonal antibodies for treating cancer," Annals of Internal Medicine (1989) 111(7):592-603.	
	34	Eildon et al., "Cytotoxicity and viability assays," Animal Cell Culture: A Practical Approach, Freshney, R.I. (Ed.), IRL Press, Oxford (1986) 186-216.	
	35	Fodor "Light-Directed, Spatially Addressable Parallel Chemical Synthesis," Science (1991) 251:767-773.	
	36	Forte et al., "Guanylin: a Peptide Regulator of Epithelial Transport," The FASEB Journal (1995) 9:643-650.	
	37	Forte et al., "Receptors and cGMP signalling mechanism for <i>E. coli</i> enterotoxin in opossum kidney," Am J Physiol (1988) 255(5Pt.2):F1040-F1046.	
	38	Forte et al., "Escherichia coli enterotoxin receptors: localization in opossum kidney, intestine, and testis," Am J Physiol (1989) 257(5Pt.2):F874-F881.	
	39	Gallop et al., "Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries," J. of Medicinal Chem. (1994) 37(9):1233-1251.	
	40	Gordon et al., "Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," J. of Medicinal Chem. (1994) 37(10):1385-1401.	
	41	Guerrant et al., "Activation of intestinal guanylate cyclase by heat-stable enterotoxin of <i>Escherichia coli</i> : studies of tissue specificity, potential receptors, and intermediates," J Infect Dis (1980) 142(2):220-228.	
	42	Hammer et al., "Promiscuous and Allele-Specific Anchors in HLA-DR-Binding Peptides," Cell (1993) 74:197-203.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/621,684
				<i>Filing Date</i>	July 17, 2003
				<i>First Named Inventor</i>	Scott A. Waldman
				<i>Art Unit</i>	1639
				<i>Examiner Name</i>	Sue Xu Liu
<i>(Use as many sheets as necessary)</i>				<i>Attorney Docket Number</i>	TJU0001-107 (WAL_SCO.001)
Sheet	4	of	7		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	43	Hamra, F. et al., "Uroguanylin: Structure and Activity of a Second Endogenous Peptide that Stimulates Intestinal Guanylate Cyclase," PNAS USA (1993) 90:10464-10468.			
	44	Helene et al., "Specific Regulation of Gene Expression by Antisense, Sense and Antigenic Nucleic Acids," Biochem. Biophys. Acta (1990) 1049:99-125.			
	45	Hughes et al., "Affinity purification of functional receptors for Escherichia coli heat-stable enterotoxin from rat intestine," Biochemistry (1992) 31(1):12-16.			
	46	Kent and Clark-Lewis in Synthetic Peptides in Biology and Medicine, pp. 295-358, Alitalo et al., eds, Science Publishers, Amsterdam (1985).			
	47	Kent and Clark-Lewis in Synthetic Peptides in Biology and Medicine, pp. 29-57, Alitalo et al., eds, Science Publishers, Amsterdam (1985).			
	48	Jain, "Barriers to Drug Delivery in Solid Tumors," Scientific American (1994) 271(1):58-65.			
	49	Kita, T. et al., "Characterization of Human Uroguanylin: a Member of the Guanylin Peptide Family," Amer. J. Physiol. (1994) 266:F342-F348.			
	50	Knyazev, P.G. et al., "Complex Characteristics of the Alterations of Oncogenes HER-2/ERBB-2, HER-1/ERBB-1, HRAS-1, C-MYC and Anti-Oncogenes p53, Rb1, as well as Deletions of Loci of Chromosome 17 in Colon Carcinoma," Molekulariarna Biologia (1992) 26(5):1134-1147 (English translation).			
	51	Krause et al., "Autoradiographic demonstration of specific binding sites for E. coli enterotoxin in various epithelia of the North American opossum," Cell Tissue Res (1990) 260(2):387-394.			
	52	Lima et al., "The effects of Escherichia coli heat-stable enterotoxin in renal sodium tubular transport," Pharmacology & Toxicology (1992) 70(3):163-167.			
	53	Melani et al., "Inhibition of Proliferation by c-myb Antisense Oligodeoxynucleotides in Colon Adenocarcinoma Cell Lines that Express c-myb," Cancer Res. (1991) 51(1):2897-2901.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
(Use as many sheets as necessary)			
Sheet	5	of	7
Attorney Docket Number			
TJU0001-107 (WAL_SCO.001)			

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	54	Nielsen et al., "Sequence-specific Transcription Arrest by Peptide Nucleic Acid Bound to the DNA Template Strand," <i>Gene</i> (1994) 149:139-145.	
	55	Ohlmeyer et al., "Complex Synthetic Chemical Libraries Indexed with Molecular Tags," <i>PNAS USA</i> (1993) 90:10922-10926.	
	56	Orkin et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," p. 41, Dec., 1993.	
	57	Ostresh et al., "Libraries from Libraries": Chemical Transformation of Combinatorial Libraries to Extend the Range and Repertoire of Chemical Diversity," <i>PNAS USA</i> (1994) 91:11138-11142.	
	58	Paxton et al., "High-specific-activity <sup>113</sup> In-labeled anticarcinoembryonic antigen monoclonal antibody: improved method for the synthesis of diethylenetriaminepentacetic acid conjugates," <i>Cancer Res</i> (1985) 45(11 Pt 2):5694-5699.	
	59	Ramsay et al., "Myb Expression is Higher in Malignant Human Colonic Carcinoma and Premalignant Adenomatous Polyps than in Normal Mucosa," <i>Cell Growth &amp; Differentiation</i> (1992) 3(10):723-30.	
	60	Rao et al., "Mode of action of heat-stable <i>Escherichia coli</i> enterotoxin. Tissue and subcellular specificities and role of cyclic GMP," <i>Biochimica et Biophysica Acta</i> (1980) 632(1):35-46.	
	61	Rodriguez-Alfageme et al., "Suppression of Deregulated c-MYC Expression in Human Colon Carcinoma Cells by Chromosome 5 Transfer," <i>PNAS USA</i> (1992) 89(4):1482-1486.	
	62	Ruggeri et al., "Inhibition of Platelet Function with Synthetic Peptides Designed to be High-affinity Antagonists of Fibrinogen Binding to Platelets," <i>PNAS USA</i> (1986) 83:5708-5712.	
	63	Schulz et al., "Cloning and expression of guanylin. Its existence in various mammalian tissues," <i>J of Biol Chem</i> (1992) 267(23):16019-16021.	
	64	Sepetov et al., "Library of Libraries: Approach to Synthetic Combinatorial Library Design and Screening of Pharmacophore Motifs," <i>PNAS USA</i> (1995) 92:5426-5430.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
(Use as many sheets as necessary)			
Sheet	6	of	7
Attorney Docket Number			
TJU0001-107 (WAL_SCO.001)			

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	65	Sizeland et al., "Antisense Transforming Growth Factor Alpha Oligonucleotides Inhibit Autocrine Stimulated Proliferation of a Colon Carcinoma Cell Line," Mol. Biol. Cell (1992) 3(11):1235-1243.	
	66	Smith et al., "A Ribonuclease S-peptide Antagonist Discovered with a Bacteriophage Display Library," Gene (1993) 128:37-42.	
	67	Takekawa et al., "Chromosomal Localization to the Protein Tyrosine Phosphatase G1 Gene and Characterization of the Aberrant Transcripts in Human Colon Cancer Cells," FEBS Letters (1994) 339(3):222-228.	
	68	Tanaka et al., "Suppression of Tumorigenicity in Human Colon Carcinoma Cells by Introduction of Normal Chromosome 1p36 Region," Oncogene (1993) 8(8):2253-2258.	
	69	Toribara et al., "Screening for Colorectal Cancer," New England J. Med. (1995) 332:861-867.	
	70	Tucker et al., "Covalent Attachment of Chelating Groups to Macromolecules," Biochem. and Biophys. Res. Communications (1977) 77(2):581-585.	
	71	Ruggeri et al., "Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets," PNAS USA (1986) 83:5708-5712.	
	72	Urbanski et al., "Internalization of E. coli ST mediated by guanylyl cyclase C in T84 human colon carcinoma cells", Biochim. Et Biophys. Acta, 1995, 1245, 29-36.	
	73	Vandraager et al., "Guanylyl Cyclase C is an N-Linked Glycoprotein Receptor That Accounts for Multiple Heat-stable Enterotoxin-binding Proteins in the Intestine," The J. of Biol. Chem. (1993) 268(3):2174-2179.	
	74	Vandraager et al., "Guanylyl cyclase C is an N-linked glycoprotein receptor that accounts for multiple heat-stable enterotoxin-binding proteins in the intestine," J. Biol. Chem. (1993) 268(3):2174-2179. (Abstract Only).	
	75	Wang et al., "Application of the Multipin Peptide Synthesis Technique for Peptide Receptor Binding Studies: Substance P as a Model System," Bioorg. & Med. Chem. Lett. (1993) 3:447-450.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/621,684
				<i>Filing Date</i>	July 17, 2003
				<i>First Named Inventor</i>	Scott A. Waldman
				<i>Art Unit</i>	1639
				<i>Examiner Name</i>	Sue Xu Liu
(Use as many sheets as necessary)					
Sheet	7	of	7	Attorney Docket Number	TJU0001-107 (WAL SCO.001)

#### NON-PATENT LITERATURE DOCUMENTS

NON-PATENT LITERATURE DOCUMENT			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	76	Weiner "An overview of monoclonal antibody therapy of cancer," Seminars Oncology (1999) 26(4 Suppl 12):41-50.	
	77	White et al., "Opossum kidney contains a functional receptor for the <i>Escherichia. coli</i> heat-stable enterotoxin," Biochemical & Biophysical Res Comm (1989) 159(1):363-367.	
	78	Yokozaki et al., "An Antisense Oligodeoxynucleotide that Depletes RI Alpha Subunit of Cyclic AMP-dependent Protein Kinase Induces Growth Inhibition in Human Cancer Cells," Cancer Research (1993) 53(4):868-872.	
	79	Yoshimura et al., "Essential structure for full enterotoxigenic activity of heat-stable enterotoxin produced by enterotoxigenic <i>Escherichia coli</i> ," FEBS (1985) 181(1):138-142.	
	80	Zuckermann et al., "Discovery of Nanomolar Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted)glycine Peptoid Library," J. Med. Chem. (1994) 37:2678-2685.	
	81	The Proteins, vol. II, 3 <sup>rd</sup> Ed., pp. 105-237, Neurath H. et al., eds, Academic Press, New York, NY 1976.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.